370 related articles for article (PubMed ID: 33515076)
1. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.
Wang T; Zhou Y; Cao G
Eur J Clin Pharmacol; 2021 Aug; 77(8):1095-1111. PubMed ID: 33515076
[TBL] [Abstract][Full Text] [Related]
2. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
Teh LK; Mohamed NI; Salleh MZ; Rohaizak M; Shahrun NS; Saladina JJ; Shia JK; Roslan H; Sood S; Rajoo TS; Muniandy SP; Henry G; Ngow HA; Hla U KT; Din J
AAPS J; 2012 Mar; 14(1):52-9. PubMed ID: 22183189
[TBL] [Abstract][Full Text] [Related]
3. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N; Lim JSL; Muerdter TE; Singh O; Cheung YB; Ng RCH; Yap YS; Wong NS; Ang PCS; Dent R; Schroth W; Schwab M; Khor CC; Chowbay B
Clin Pharmacokinet; 2016 Oct; 55(10):1239-1250. PubMed ID: 27098059
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.
Kiyotani K; Mushiroda T; Nakamura Y; Zembutsu H
Drug Metab Pharmacokinet; 2012; 27(1):122-31. PubMed ID: 22041137
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA; Goetz MP; Brauch H; Flockhart DA; Hebert JM; Whaley R; Suman VJ; Schroth W; Winter S; Zembutsu H; Mushiroda T; Newman WG; Lee MT; Ambrosone CB; Beckmann MW; Choi JY; Dieudonné AS; Fasching PA; Ferraldeschi R; Gong L; Haschke-Becher E; Howell A; Jordan LB; Hamann U; Kiyotani K; Krippl P; Lambrechts D; Latif A; Langsenlehner U; Lorizio W; Neven P; Nguyen AT; Park BW; Purdie CA; Quinlan P; Renner W; Schmidt M; Schwab M; Shin JG; Stingl JC; Wegman P; Wingren S; Wu AH; Ziv E; Zirpoli G; Thompson AM; Jordan VC; Nakamura Y; Altman RB; Ames MM; Weinshilboum RM; Eichelbaum M; Ingle JN; Klein TE;
Clin Pharmacol Ther; 2014 Feb; 95(2):216-27. PubMed ID: 24060820
[TBL] [Abstract][Full Text] [Related]
7. Understanding CYP2D6 and its role in tamoxifen metabolism.
Smith EC
Oncol Nurs Forum; 2013 Nov; 40(6):547-8. PubMed ID: 24161632
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
9. Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.
Lim JS; Sutiman N; Muerdter TE; Singh O; Cheung YB; Ng RC; Yap YS; Wong NS; Ang PC; Dent R; Schroth W; Schwab M; Chowbay B
Br J Clin Pharmacol; 2016 Jun; 81(6):1142-52. PubMed ID: 26799162
[TBL] [Abstract][Full Text] [Related]
10. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.
Brauch H; Schwab M
Br J Clin Pharmacol; 2014 Apr; 77(4):695-703. PubMed ID: 24033728
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?
Huber-Wechselberger AE; Niedetzky P; Aigner I; Haschke-Becher E
Wien Med Wochenschr; 2012 Jun; 162(11-12):252-61. PubMed ID: 22688624
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and CYP2D6: a contradiction of data.
Hertz DL; McLeod HL; Irvin WJ
Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
[TBL] [Abstract][Full Text] [Related]
14. Design and implementation of a novel pharmacogenetic assay for the identification of the CYP2D6*10 genetic variant.
Ranadeva NDK; Sirisena ND; Wetthasinghe TK; Noordeen N; Dissanayake VHW
BMC Res Notes; 2022 Mar; 15(1):104. PubMed ID: 35296326
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
16. Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.
Puszkiel A; Arellano C; Vachoux C; Evrard A; Le Morvan V; Boyer JC; Robert J; Delmas C; Dalenc F; Debled M; Venat-Bouvet L; Jacot W; Suc E; Sillet-Bach I; Filleron T; Roché H; Chatelut E; White-Koning M; Thomas F
Clin Pharmacol Ther; 2019 Sep; 106(3):585-595. PubMed ID: 30786012
[TBL] [Abstract][Full Text] [Related]
17. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract][Full Text] [Related]
19. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects.
Keller DN; Medwid SJ; Ross CD; Wigle TJ; Kim RB
Pharmacogenet Genomics; 2023 Jan; 33(1):10-18. PubMed ID: 36373739
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
